Inclusion Criteria:

          -  Patients must have histologically or cytologically documented newly diagnosed de novo
             Acute Myeloid Leukemia (non-APL) that has not yet been treated. Hydrea and ATRA
             previous treatments are acceptable.

          -  Patients must not have a secondary AML (defined as a history of prior radiation
             therapy or systemic chemotherapy, CMML or MDS not treated with a hypomethylating
             agent) however history of previous MDS treated with a hypomethylating agent IS
             allowed.

          -  Hydroxyurea may be used to control leukocytosis, provided that it is without Grade >2
             toxicity, and can be taken until start of therapy.

          -  Age >60 years.

          -  ECOG performance status of ≤ 2 and fit for induction therapy in the opinion of the
             treating physician.

          -  Laboratory values ≤2 weeks must be:

          -  AST(SGOT)/ALT(SGPT)≤ 2.5 X institutional upper limit of normal

          -  Bilirubin ≤ 2 X ULN (3X if known history of Gilbert'syndrome)

          -  Creatinine clearance (CrCl) must be > 20 mL/min

          -  Baseline left ventricular ejection fraction of at least 40% by MUGA or ECHO.

          -  Female patients of childbearing potential must agree to use 2 methods of contraception
             (including 1 highly effective and 1 effective method of contraception) and have a
             negative serum pregnancy test at Screening. Male patients must use an effective
             barrier method of contraception if sexually active with a female of childbearing
             potential. For both male and female patients, effective methods of contraception must
             be used throughout the study and for 3 months following the last dose of study
             treatment. Please refer to Section 6.4.4 of this protocol.

          -  Ability to understand and the willingness to sign an IRB-approved informed consent
             document.

        Exclusion Criteria:

          -  Patients who have received any therapy other than hydroxyurea or ATRA with the purpose
             of treating their AML or patients with Acute Promyelocytic Leukemia are not eligible.

          -  Patients with a secondary AML (defined as a history of prior radiation therapy or
             systemic chemotherapy, CMML or MDS not treated with a hypomethylating agent) however
             history of previous MDS treated with a hypomethylating agent IS allowed.

          -  Patients having received prior radiotherapy, treatment with cytotoxic agents,
             treatment with biologic agents or any anti-cancer therapy for a non-AML malignancy
             within the 4 weeks prior to treatment with selinexor, or those who have not fully
             recovered from the acute, non-hematological, non-infectious toxicities of any prior
             treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned
             to baseline status as noted before most recent treatment).

          -  Patients with another active malignancy that requires treatment excluding non-melanoma
             skin cancers.

          -  Patients that have received a chemotherapy regimen with stem cell support in the
             previous 6 months.

          -  Patients with known central nervous system involvement should be excluded from this
             clinical trial because the penetration of selinexor into the CNS is not currently
             known.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to selinexor.

          -  Uncontrolled concurrent illness including, but not limited to symptomatic congestive
             heart failure, unstable angina pectoris, or cardiac arrhythmia

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Patients with known HIV infection or hepatitis (Note: Patients with known HIV
             infection are excluded because patients with an immune deficiency are at increased
             risk of lethal infections when treated with marrow-suppressive therapy.

          -  Pregnant women are excluded from this study because of the potential for teratogenic
             or abortifacient effects. Because there is an unknown but potential risk for adverse
             events in nursing infants secondary to treatment of the mother, breastfeeding should
             be discontinued.

          -  Patients unable to swallow tablets, patients with malabsorption syndrome, or any other
             GI disease or GI dysfunction that could interfere with absorption of study treatment

          -  Prior exposure to a SINE compound